14.05
+4.07%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Q linea
Its shares trade on Nasdaq Stockholm under the ticker QLINEA.ST. It has been listed since 7 December 2018. In the fiscal year to 31 December 2025, it reported revenue of SEK 11.1m and a net loss of SEK 182.5m. At that date it held total assets of SEK 369.7m and shareholders' equity of SEK 338.0m.
Q-linea AB operates as a holding company. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2018-12-07. The firm develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The firm's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). The company measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. The company is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 7 Dec 2018
- Employees
- 122
- Website
- qlinea.com ↗
Leadership
Pay as last reported
- Mr. Johan ByggeIndependent Chairman of the Board
- Mr. Stuart GanderChief Executive Officer
- Mr. Mario GualanoDeputy Independent Chairperson of the BoardSEK 338,000
- Mr. Christer SamuelssonChief Financial Officer and Investor Relations
- Mr. Henrik JacobsonChief Operating Officer, Production Manager
- Mr. Franco PellegriniVice President - Sales, EMEA
- Mr. Jim KathreinVice President - US Commercial Operations
- Mr. Anders LjunggrenManaging Director, Manager - Project Management OfficeSEK 2.7m
- Ms. Victoria LernerydManager - QA/RA
- Mr. Jonas MelinDirector - Product Development
- Mr. Karl SkoeldDirector Contract Development
- Ms. Erika ErikssonDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 27
- Environment
- 23
- Social
- 41
- Governance
- 17
- Women in the workforce
- 43.61702%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company develops and manufactures in-vitro diagnostic solutions for infectious diseases.
- The core product ASTar provides susceptibility profiles within three to six hours from positive blood cultures.
- The company is headquartered in Uppsala with 122 employees and an IPO in 2018.
Weaknesses
- The company operates as a holding company without specified operational details.
- The source description treats the company as untrusted, indicating potential reliability issues.
- The firm's product is primarily aimed at hospital laboratories, limiting market scope.
Opportunities
- The product ASTar targets sepsis identification, a critical healthcare need.
- Early antibiotic administration based on susceptibility profiles could improve patient outcomes.
- The company's focus on infectious disease diagnostics aligns with growing healthcare demands.
Threats
- The source description is untrusted, raising questions about the accuracy of provided information.
- The company's reliance on a single product candidate (ASTar) poses business risk.
- The healthcare sector faces regulatory and competitive challenges that may impact operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.